Core Insights - Eterna Therapeutics is advancing its induced mesenchymal stem cell (iMSC) therapy programs for treating advanced solid tumors and autoimmune diseases, with a successful inaugural meeting of its Scientific Advisory Board focusing on preclinical advances and clinical trial roadmaps [1][2][3] Company Overview - Eterna Therapeutics (Nasdaq: ERNA) specializes in innovative cell therapies, particularly through engineering induced pluripotent stem cells (iPSCs) into iMSCs, offering scalable, off-the-shelf treatment solutions without the need for patient-specific cell harvesting [4] Product Development - The company is developing two lead products: ERNA-101, aimed at activating the immune system to target cancer cells, and ERNA-102, designed to address inflammation in autoimmune diseases, with a primary focus on ovarian cancer for ERNA-101 [5][8] Scientific Advisory Board Insights - The Scientific Advisory Board includes leading experts who engaged in discussions about advancing next-generation cell therapies, emphasizing the importance of scientific rigor and innovation [2][7] - Highlights from the meeting included positive preclinical data for ERNA-101, strategies for optimizing dosage and administration routes, and potential combination therapies with CAR-T therapy and other immunomodulatory approaches [8] Future Directions - Eterna plans to continue collaboration with the Scientific Advisory Board and stakeholders to translate innovative therapies into clinical practice, with a focus on rigorous quality, safety, and efficacy criteria [3][8]

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (NASDAQ:ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome Zeldis, M.D., Ph.D., and Blythe Sather, Ph.D., to the company's scientific advisory board. "We are fortunate to welcome Dr. Zeldis and Dr. Sather," said Sanjeev Luther, President & CEO of Eterna Therapeutics. "Their extensive experience in developing transformative, high-profile cell therapies for solid tumors has ...

New data from proof-of-concept study provides roadmap for treatment of ovarian cancerCAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced positive results from a preclinical study on the company’s lead cell therapy product, ERNA-101, which is designed to activate and regulate the immune system's response to recognize and attack ovarian cancer cells. This successful proof-of-concept study ...

Company Announcement - Eterna Therapeutics appoints Dr Elena Ratner to its Board of Directors to lead strategic efforts in ovarian cancer research and treatment [1][2] - Dr Ratner brings extensive expertise in obstetrics gynecology and reproductive sciences from Yale University [1][4] - Eterna aims to accelerate advancements in innovative therapies for ovarian and breast cancers leveraging Dr Ratner's leadership and recent collaboration with MD Anderson Cancer Center [2] Product Development - Eterna's lead product ERNA-101 is an allogeneic pro-inflammatory cytokine (IL-7/IL-15)-secreting iMSC therapy targeting platinum-resistant ovarian cancer [5] - ERNA-101 enhances immune system response against tumors by improving immune cell infiltration and activation [3] - The company is also investigating ERNA-102 anti-inflammatory cytokine (IL-10)-secreting iMSCs for inflammatory/auto-immune disorders like rheumatoid arthritis [5] Strategic Direction - Eterna is actively seeking strategic partnerships to co-develop or out-license therapeutic assets and expand developmental opportunities [5] - The company's focus on women's health is reinforced by its collaboration with MD Anderson Cancer Center and Dr Ratner's expertise [2][4] - Eterna's scientific data shows promise in addressing the challenges of ovarian cancer treatment including resistance and high recurrence rates [3]

CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) announced today that it has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market. Eterna received formal confirmation on November 12th, 2024 from Nasdaq’s Office of General Counsel, verifying that Eterna has met the market value of listed securities standard of at least $35 million, outlined in Listing Rule 5550(b)(2), a ...

Financing Activities - The company closed a private placement on October 29, 2024, selling 1,401,994 shares and pre-funded warrants for approximately $1.1 million in gross proceeds[147]. - The company issued 38,302,029 shares in exchange for approximately $8.7 million in convertible notes and warrants, with an exercise price of $1.43 per share[148]. - The company converted approximately $3.0 million of bridge notes into 6,244,237 shares at a conversion price of $0.50[152]. - The company regained compliance with Nasdaq listing rules after issuing over 45.9 million shares, resulting in stockholders' equity exceeding $2.5 million[163]. Revenue and Income - Revenue for the three months ended September 30, 2024, was $487 million, a significant increase of $436 million compared to $51 million for the same period in 2023[172]. - Gross income for the three months ended September 30, 2024, was $547 million, compared to a loss of $69 million in the same period in 2023, reflecting a change of $616 million[172]. - The company recognized approximately $0.5 million in previously deferred revenue related to the Lineage Agreement for the three and nine months ended September 30, 2024[165]. Expenses - Research and development expenses include costs for company-sponsored activities and support for investigator-sponsored research, with major components being salaries, supplies, and preclinical study costs[167][168]. - Research and development expenses decreased by approximately $0.4 million for the three months ended September 30, 2024, totaling $1,001 million, down from $1,387 million in the same period in 2023[175]. - General and administrative expenses for the three months ended September 30, 2024, were $3,381 million, a decrease of $668 million compared to $4,049 million for the same period in 2023[176]. - Total research and development expenses for the nine months ended September 30, 2024, were $3,446 million, down from $4,560 million in the same period in 2023, a decrease of $1.1 million[175]. - The total operating expenses for the three months ended September 30, 2024, were $2,806 million, a decrease of $2,630 million compared to $5,436 million for the same period in 2023[172]. Net Loss and Financial Position - The net loss for the three months ended September 30, 2024, was $26.6 million, compared to a net loss of $5.6 million for the same period in 2023, reflecting an increase in loss of $21 million[172]. - For the nine months ended September 30, 2024, the company incurred a net loss of approximately $38.8 million, compared to a net loss of $15.7 million for the same period in 2023, indicating a significant increase in losses[190]. - As of September 30, 2024, the company had cash of approximately $4.3 million and an accumulated deficit of approximately $225.8 million[190]. - The company anticipates that it will not have sufficient capital to fund operations for the next 12 months, raising concerns about its ability to continue as a going concern[193]. Other Financial Metrics - A loss on extinguishment of debt was recorded at $22.4 million for the three and nine months ended September 30, 2024, with no similar transaction in the prior year[181]. - The company recognized an increase in interest expense of approximately $3.2 million for the nine months ended September 30, 2024, primarily due to convertible note financings[187]. - The net cash used in operating activities decreased by approximately $3.5 million for the nine months ended September 30, 2024, compared to the same period in 2023[199]. - The company recognized a credit of $0.1 million for the change in the fair value of contingent consideration liability for both the nine months ended September 30, 2023, and 2024[185]. Strategic Initiatives - The company plans to complete IND enabling studies and submission for its lead product ERNA-101 by 2026, focusing on triple negative breast cancer and platinum-resistant ovarian cancer[146]. - The company is actively seeking strategic partnerships to co-develop or out-license therapeutic assets to expand developmental opportunities[146]. - The company entered into an Exclusive License and Collaboration Agreement with Factor Bioscience, committing to pay $0.2 million per month for the first twelve months[154][156]. Legal and Compliance - No changes in internal control over financial reporting during the most recent fiscal quarter that materially affected internal controls[211]. - Company is not party to any material legal proceedings, except those described in the financial statements[212]. Lease and Property - The company recognized a gain on lease termination of approximately $1.6 million and expects to save about $72 million in future rental payments due to the termination of a sublease[161]. - The company used approximately $0.3 million for property and equipment purchases during the nine months ended September 30, 2024, with no investing activities in the same period of 2023[200].

CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company") today announced the successful completion of a comprehensive financial restructuring of the Company with the aim to accelerate its developmental activities and long-term success. This restructuring includes reduction of its liabilities by discontinuing a longstanding lease, reducing the debt on its balance sheet and a new round of financing through a private investment in public equity (PI ...

CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company") and Factor Bioscience Limited ("Factor") today announced an exclusive license and collaboration agreement aimed at accelerating the development of advanced cell therapy candidates for oncology, rare diseases, and autoimmune disorders. Under the terms of the agreement, Eterna has secured a worldwide, exclusive, non-transferable, royalty-bearing license, with the right to grant sublicenses, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol Name of each exchange on which registered Common stock, $0.005 par value per share ERNA The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _____________ Commission file number: 001-11460 Eterna Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 31-11034 ...